跳至主要内容
临床试验/NCT03239158
NCT03239158已完成2 期

Combination of Cancer Ablation and Life Information Rehabilitation Therapy for Unresectable Liver Cancer

Fuda Cancer Hospital, Guangzhou1 个研究点 分布在 1 个国家目标入组 120 人开始时间: 2017年9月2日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
120
试验地点
1
主要终点
Relief degree of tumors

研究概览

简要总结

The aim of this study is the synergistic effect of cancer ablation and life information rehabilitation therapy on unresectable liver cancer.

详细描述

By enrolling patients with unresectable liver cancer adapted to enrolled criteria, this study will document for the first time the synergistic effect of cancer ablation and life information rehabilitation therapy. The efficacy will be evaluated according to local relief degree, progress free survival (PFS) and overall survival (OS).

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
30 Years 至 80 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • All standard therapies have failed according to NCCN guidelines or the patient refuses standard therapies
  • Body tumor 1-6, with at least one tumor length > 2 cm
  • KPS ≥ 70, lifespan > 6 months
  • Platelet count ≥ 80×109/L,white blood cell count ≥ 3×109/L, neutrophil count ≥ 2×109/L, hemoglobin ≥ 80 g/L

排除标准

  • Patients with cardiac pacemaker
  • Patients with brain metastasis
  • Patients with grade 3 hypertension or diabetic complication, severe cardiac and pulmonary dysfunction

研究组 & 干预措施

Cancer ablation

Active Comparator

In this group, the patients will receive ablation therapy (e.g. cryosurgery or irreversible electroporation) first for big tumors (> 2 cm). The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

干预措施: Cancer ablation (Device)

Life information rehabilitation therapy

Active Comparator

In this group, the patients will drink "Qilisheng" Immunoregulatory Oral Solution for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

干预措施: Life information rehabilitation therapy (Drug)

Combination therapy

Experimental

In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then "Qilisheng" Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

干预措施: Cancer ablation (Device)

Combination therapy

Experimental

In this group, the patients will receive the combination therapy including ablation and life information rehabilitation therapy. The ablation therapy (e.g. cryosurgery or irreversible electroporation) will be performed first for big tumors (> 2 cm), then "Qilisheng" Immunoregulatory Oral Solution will be provided for consecutive 3 months. The check indexes are CT scan and blood tests (including tumor markers, lymphocyte subsets and circulating tumor cell).

干预措施: Life information rehabilitation therapy (Drug)

结局指标

主要结局

Relief degree of tumors

时间窗: 3 months

It will be evaluated by the Response Evaluation Criteria in Solid Tumors(RECIST)

次要结局

  • Overall survival(OS)(3 years)
  • Progress free survival(PFS)(1 year)

研究者

发起方
Fuda Cancer Hospital, Guangzhou
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验